BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Aviir Diagnostic Laboratories Secures $8 Million in Funding From Silicon Valley Bank


9/20/2012 10:52:57 AM

IRVINE, Calif., Sept. 19, 2012 /PRNewswire/ -- Aviir Inc., a biotechnology company dedicated to the prevention of cardiovascular disease through innovative laboratory tests, announced today that it has secured $5 million in growth debt capital and a $3 million line of credit on receivables from Silicon Valley Bank to accelerate commercialization activities and infrastructure build-out for its cardiac risk assessment portfolio of laboratory tests targeted at fostering cardiac disease prevention.

"This loan strengthens our financial position in conjunction with our December 2012 capital financing of up to $30 million led by Merck GHI and gives us the ability to focus on commercialization and market penetration," said Douglas Harrington, MD, CEO of Aviir. "We greatly value our relationship with Silicon Valley Bank and we are confident of executing our plan to bring our proprietary cardiac risk and inherited cardiovascular disease disorder assays to market to improve healthcare and enable preventive strategies based on Aviir's critical and unique information."

"It's our mission to help innovative life science companies, like Aviir, succeed," said Robert Anderson, Senior Relationship Manager with Silicon Valley Bank. "We make every effort to provide the expertise and financing our clients need as they grow and develop solutions for critical medial concerns. In the case of Aviir, its strong leadership team and pioneering technology is identifying people who may be at risk of cardiac failure, which is exactly the profile of cutting-edge technology and innovation that make a relationship between SVB and our clients so rewarding."

About Silicon Valley Bank
Silicon Valley Bank is the premier bank for technology, life science, cleantech, venture capital, private equity and premium wine businesses. SVB provides industry knowledge and connections, financing, treasury management, corporate investment and international banking services to its clients worldwide through 27 U.S. offices and seven international operations. (NASDAQ: SIVB) www.svb.com. Silicon Valley Bank is the California bank subsidiary and the commercial banking operation of SVB Financial Group. Banking services are provided by Silicon Valley Bank, a member of the FDIC and the Federal Reserve System. SVB Private Bank is a division of Silicon Valley Bank. SVB Financial Group is also a member of the Federal Reserve System.

About Aviir
Aviir was founded in 2005 by cardiologists and scientists from the Stanford University School of Medicine to focus on discovery, development and commercialization of innovative diagnostic tests. The biotechnology company specializes in developing proprietary diagnostic tests that will assist in identifying patients that are truly at high risk for the development of a cardiac event. Aviir's proprietary MIRisk and TruRisk assessments objectively identify, by a simple blood draw, individuals who are at a high risk of a cardiac event over the next five years. Aviir's CLIA laboratory (Irvine, CA) complements these novel tests with a wide range of additional tests for risk assessment and therapeutic monitoring of cardiovascular disease and related metabolic disorders including pharmacogenomic and genetic tests. The company has adopted a unique clinical laboratory service model to provide physicians better diagnostic tools that improve cardiovascular health of their patients. The company is privately owned and funded by leading life science venture capital firms. Please visit www.aviir.com for more information.

For media inquiries, please contact:
Dina Scaglione
(949)910-9401
dina.scaglione@aviir.com

SOURCE Aviir Inc.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES